Perspective Therapeutics develops cancer drugs that deliver targeted radiation to tumors, paired with imaging tools to guide treatment. CATX reports earnings on Mon, Nov 9, 2026. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for CATX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CATX is in one of them and how their past CATX trades turned out.
Perspective Therapeutics is a radiopharmaceutical development company based in Seattle, Washington. It is developing cancer treatments that attach a radioactive isotope known as lead 212 to targeting molecules, which are designed to carry radiation directly to cancer cells. The company also develops imaging agents using a related isotope so that doctors can locate tumors before treatment. Its lead candidates are in clinical trials in the United States for neuroendocrine tumors, melanoma and other solid tumors. The intended users of these treatments are cancer patients and the clinicians who treat them, and the company is building its own manufacturing capacity.
